Sample ID,Disease,Gene,Repeat Status,Sex,Median depth,Read length,Experimental size,Mutations,Source,CommentsNA06075,DM1,DMPK,Expansion,Male,37.8913103558857,150,66,(CTG)n EXPANSION,Illumina,Clinical status unknown; droopy eyelids; stiff when cold; cardiac arrhythmia; donor subject has one normal CTG repeat allele and one allele with a CTG repeat size of 66 in the DMPK gene; affected daughter is GM04608; two affected granddaughters are GM04601 and GM06077; EMG exam was normal; see GM06076 fibroblastNA04567,DM1,DMPK,Expansion,Female,45.3836370949791,150,700,(CTG)n EXPANSION,Illumina,"Clinically affected; first reported episode of weakness occurred at age 8, which was diagnosed as dermatomyositis; distal weakness; myopathic facies; long, thin face; clinical and electrical myotonia; occasional hand cramping; marked lid lag; distal atrophy of hands and feet; reduced muscle mass; difficulty swallowing; marked myotonic response with percussion of the tongue; absent deep tendon reflexes in ankles and knees and markedly depressed reflexes in biceps and triceps; receding hairline; EMG exam revealed ""Evidence of a diffuse myopathic process which actually is maximal distally. There is also ample evidence of myotonic insertional potentials present.""; donor subject has one normal CTG repeat allele and one allele with a CTG repeat size of approximately 700 in the DMPK gene; affected sister is GM05164"NA05164,DM1,DMPK,Expansion,Female,44.8212192275127,150,340,(CTG)n EXPANSION,Illumina,Clinically affected; hand cramping present since childhood; difficulty swallowing; myotonic facies; lack of facial expression; myotonia evident with grip and with percussion of the thenar eminence; significant weakness in the hands; marked weakness of neck flexors; weakness in the foot-toe extensors and foot dorsiflexors; difficulty getting pregnant; donor subject has one normal CTG repeat (21) allele and one allele with a CTG repeat size of approximately 340 in the DMPK gene; affected sister is GM04567; see GM05163 fibroblastNA04648,DM1,DMPK,Expansion,Male,49.4839109881726,150,1000,(CTG)n EXPANSION,Illumina,Clinically affected; diagnosed at age 22; bilateral cataracts; frontal baldness; bilateral ptosis; limitation of full lid closure; myotonic ocular response; facial diparesis; diminished phonation amplitude; weakness of intrinsic muscles of the face; myotonic lingual response; loss of muscle bulk to the hands; depressed deep tendon reflexes; myotonia evident with hand grip and after thenar percussion; weakness to the extensors and flexors of the wrist and to the intrinsic muscles of the hands; donor subject has one normal CTG repeat allele and one allele with a CTG repeat size of approximately 1000 (minor species at ~700-800) in the DMPK gene; affected father is GM04573; affected grandfather is GM05142; affected paternal aunt is GM05281; see GM04647 fibroblastNA05152,DM1,DMPK,Expansion,Male,49.957055124701,150,1500,(CTG)n EXPANSION,Illumina,"Clinically affected; weakness in hands noted at age 43; pain in calf muscles after walking and fatigue in legs; problems with balance; palmar erythema on the hands; slight ataxia in lower extremities; slight lordosis; hypoactive reflexes; weakness in all extremity muscles; abnormal esophageal motility; long, thin face; thin extremities and thin chest; weakness of neck flexion; myotonia; myopathic facies; muscle biopsy showed ""type I fiber atrophy which is characteristic of myotonic dystrophy""; EMG exam was ""consistent with a polyneuropathy and tardy ulnar palsy""; donor subject has one normal CTG repeat allele and one allele with a CTG repeat size of approximately 1500 in the DMPK gene; see GM05151 fibroblast"NA23378,DM1,DMPK,Expansion,Male,47.2227176270589,150,80-90,(CTG)n EXPANSION,Illumina,Clinically affected; mild phenotype; two affected children; onset of symptoms at age 50 years; donor subject has one normal CTG repeat allele and one allele with a CTG repeat size of approximately 80-90 in the DMPK geneNA23374,DM1,DMPK,Expansion,Female,44.385104751338,150,130-140,(CTG)n EXPANSION,Illumina,Clinically affected; onset of symptoms at age 27 years; began using a walker at age 38; hand stiffness; problems making a fist; problems speaking; difficulty swallowing; facial weakness; problems with ankles; problems rising from a sitting position; difficulty breathing; donor subject has one normal CTG repeat allele and one allele with a CTG repeat size of approximately 130-140 in the DMPK geneNA23300,DM1,DMPK,Expansion,Male,46.311265943196,150,150-160,(CTG)n EXPANSION,Illumina,Clinically affected; onset of symptoms at age 29 years; hand stiffness; problems making a fist; problems speaking; difficulty swallowing; facial weakness; problems with ankles; problems rising from a sitting position; cataracts; baldness; donor subject has one normal CTG repeat allele and one allele with a CTG repeat size of approximately 150-160 in the DMPK geneNA03986,DM1,DMPK,Expansion,Male,48.1201955851949,150,500,(CTG)n EXPANSION,Illumina,Distal weakness; clinical and electrical (EMG) myotonia; cataracts; marked balding; see GM03987 Fibroblast; expansion of CTG repeat is <1.5 kb detectable by Southern analysis corresponding to up to 500 CTG repeatsNA03989,DM1,DMPK,Expansion,Male,47.0162011532907,150,2000,(CTG)n EXPANSION,Illumina,Distal weakness; frontal baldness; cataracts; clinical and electrical (EMG) myotonia; expansion of CTG repeat greater than or equal to 4.5 kb by Southern analysis corresponding to up to 2000 CTG repeatsNA03990,DM1,DMPK,Expansion,Female,45.9355994705292,150,50-80,(CTG)n EXPANSION,Illumina,"Distal weakness; cataracts; clinical and electrical myotonia; frontal baldness; see GM03991 Fibroblast; 50 to 80 CTG repeats detectable by PCR, no visible expansion by Southern analysis"NA03696,DM1,DMPK,Expansion,Female,47.6507833352643,150,1000,(CTG)n EXPANSION,Illumina,Family history of clinical phenotype; EMG myotonia and mild myopathic facies; affected father is GM03759A Fibroblast; expansion of CTG repeat is 1.5 to 3.0 kb by Southern analysis corresponding to up to 1000 CTG repeatsNA03759,DM1,DMPK,Expansion,Male,47.8684448289356,150,2000,(CTG)n EXPANSION,Illumina,EMG myotonia; myotonic face; distal weakness and atrophy; positive family history; affected daughter is GM03696C Lymphoid; expansion of CTG repeat is greater than or equal to 4.5 kb by Southern analysis corresponding to up to 2000 CTG repeatsNA04034,DM1,DMPK,Expansion,Male,45.9974818101159,150,1000,(CTG)n EXPANSION,Illumina,Temporal atrophy; clinical myotonia; distal weakness; positive family history; see GM04033 Fibroblast; expansion of CTG repeat is 1.5 to 3.0 kb detectable by Southern analysis corresponding to up to 1000 CTG repeatsNA03697,DM1,DMPK,Expansion,Male,48.0665903444852,150,500,(CTG)n EXPANSION,Illumina,Myotonic face; EMG myotonia; distal atrophy; positive family history; expansion of CTG repeat is <1.5 kb detectable by Southern analysis corresponding to up to 500 CTG repeatsNA03132,DM1,DMPK,Expansion,Male,44.3056388859679,150,1700,(CTG)n EXPANSION,Illumina,"Bone deformities; muscle wasting and myotonia; one DMPK allele harbors approximately 1700 copies of the CTG trinucleotide repeat, as assayed by Southern analysis; the other DMPK allele is normal, with 5 copies of the CTG trinucleotide repeat, as detected by PCR."NA03756,DM1,DMPK,Expansion,Male,48.138161045742,150,500,(CTG)n EXPANSION 677C>T,Illumina,"Typical phenotype; mother, 2 brothers, and a sister are also affected; see GM03755 Fibroblast; expansion of CTG repeat is <1.5 kb detectable by Southern analysis corresponding to up to 500 CTG repeats; heterozygous for a C-to-T substitution at nucleotide 677 that converts an alanine to a valine residue in the methylenetetrahydrofolate reductase (MTHFR) gene (677C-T)"NA13716,DRPLA,ATN1,Expansion,Male,46.6752390737322,150,68,(CAG)n EXPANSION,Illumina,Hyperactivity & short attention span at age 7; at age 8 showed developmental & cognitive regression; significantly demented at age 12; recurrent generalized tonic-clonic seizures; DRPLA CAG expansion repeat alleles are 16 and 68NA13717,DRPLA,ATN1,Expansion,Male,49.3516790260551,150,65,(CAG)n EXPANSION,Illumina,"Progressive neurodegenerative disorder; ataxia, cognitive impairment, dementia, choreiform movements, and speech difficulties; seizure disorder at age 46; DRPLA CAG expansion repeat alleles are 15 and 65"NA03816,FRDA,FXN,Double Expansion,Female,46.67650189864,150,330/380,(GAA)n EXPANSION,Illumina,Clinically affected; spinal-cerebral degeneration with myocardiopathy; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 330 and 380 repeats; a brother (GM04078/GM04079) is similarly affected.NA04079,FRDA,FXN,Double Expansion,Male,48.7115103074178,150,420/540,(GAA)n EXPANSION,Illumina,Clinically affected; ataxia; cardiomyopathy; mild peripheral neuropathy; proband is GM03816; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 541 and 420 repeats; see GM04078 Fibroblast.NA14519,FRDA,FXN,Carrier,Female,47.5442474725129,150,9/1285,(GAA)n EXPANSION,Illumina,Clinically unaffected carrier; mother of affected child (GM14518); donor subject has alleles with GAA triplet repeat expansions of 9 repeats and 1285 + 50 repeats in the first intron of the frataxin gene.NA15850,FRDA,FXN,Double Expansion,Male,48.4070835546991,150,650/1030,(GAA)n EXPANSION,Illumina,"Clinically affected; ataxia; scoliosis; hypertrophic cardiomyopathy; slurred speech; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 650 and 1030 repeats; brother of GM15849 and GM15851, son of GM15847 and GM15848."NA15847,FRDA,FXN,Carrier,Female,45.3969017601425,150,760,(GAA)n EXPANSION,Illumina,"Clinically unaffected carrier; mother of one affected child (GM15850), a carrier (GM15849), & one normal child (GM15851); donor subject has one allele with GAA triplet repeat expansions of 760 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits."NA15848,FRDA,FXN,Carrier,Male,48.8163623067898,150,830,(GAA)n EXPANSION,Illumina,"Clinically unaffected carrier; father of one affected child (GM15850), a carrier (GM15849), & one normal child (GM15851); donor subject has one allele with GAA triplet repeat expansions of 830 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits."NA16197,FRDA,FXN,Double Expansion,Male,49.011773803386,150,760/830,(GAA)n EXPANSION,Illumina,Clinically affected; onset at 8 1/2 years of age; ataxia; mild cardiomyopathy; areflexia; weakness; sensory loss; scoliosis with spinal fusion; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 760 and 830 repeats.NA16200,FRDA,FXN,Carrier,Female,48.3788747715724,150,830,(GAA)n EXPANSION,Illumina,Clinically unaffected carrier; mother of an affected son (GM16197); donor subject has one allele with GAA triplet repeat expansion of 830 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits.NA16202,FRDA,FXN,Carrier,Female,48.9736910643482,150,830,(GAA)n EXPANSION,Illumina,Clinically unaffected carrier; mother of an affected daughter (GM16203); donor subject has one allele with GAA triplet repeat expansion of 830 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits.NA16203,FRDA,FXN,Double Expansion,Female,50.178252822613,150,670/830,(GAA)n EXPANSION,Illumina,Clinically affected; onset at 6 years of age; ataxia; areflexia; sensory loss; dysarthria; scoliosis; hearing loss; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 670 and 830 repeats.NA16205,FRDA,FXN,Double Expansion,Male,50.1438742707232,150,530/530,(GAA)n EXPANSION,Illumina,Clinically affected; onset at 12 years of age; ataxia; weakness; sensory loss; homozygous for the GAA expansion in the frataxin gene with both alleles of approximately 530 repeats.NA16209,FRDA,FXN,Double Expansion,Female,49.7465418047206,150,800/800,(GAA)n EXPANSION,Illumina,Clinically affected; age of onset 10; ataxia; cardiomyopathy; areflexia; weakness; sensory loss; dysarthria; scoliosis; nystagmus; homozygous for the GAA expansion in the frataxin gene with both alleles of approximately 800 repeats.NA16210,FRDA,FXN,Double Expansion,Male,50.6924982255759,150,580/580,(GAA)n EXPANSION,Illumina,Clinically affected; onset at 17 years of age; ataxia; areflexia; weakness; sensory loss; dysarthria; scoliosis; reduced visual acuity; hearing loss; homozygous for the GAA expansion in the frataxin gene with both alleles of approximately 580 repeats.NA16212,FRDA,FXN,Carrier,Female,48.5349056570965,150,500,(GAA)n EXPANSION,Illumina,Clinically unaffected carrier; mother of an affected son (GM16210); donor subject has one allele with GAA triplet repeat expansion of 500 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits.NA16216,FRDA,FXN,Double Expansion,Female,44.7817342128224,150,200/500,(GAA)n EXPANSION,Illumina,Clinically affected; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 200 and 500 repeats.NA16213,FRDA,FXN,Carrier,Male,44.5299974688847,150,420,(GAA)n EXPANSION,Illumina,Clinically unaffected carrier; father of an affected daughter (GM16216); donor subject has one allele with GAA triplet repeat expansion of 420 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits.NA16215,FRDA,FXN,Carrier,Female,43.7743626897201,150,830,(GAA)n EXPANSION,Illumina,Clinically unaffected carrier; mother of an affected son (GM16214); donor subject has one allele with GAA triplet repeat expansion of 830 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits.NA16214,FRDA,FXN,Double Expansion,Male,45.6132431893262,150,600/700,(GAA)n EXPANSION,Illumina,Clinically affected; onset at 9 years of age; ataxia; cardiomyopathy; areflexia; weakness; scoliosis; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 600 and 700 repeats.NA16227,FRDA,FXN,Double Expansion,Female,43.948140903016,150,630/830,(GAA)n EXPANSION,Illumina,Clinically affected; onset at 13 years of age; ataxia; areflexia; weakness; sensory loss; scoliosis; affected sister is GM16228; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 630 and 830 repeats.NA16229,FRDA,FXN,Carrier,Female,45.0444932568123,150,670,(GAA)n EXPANSION,Illumina,Clinically unaffected carrier; mother of two affected daughters (GM16227 and GM16228); donor subject has one allele with GAA triplet repeat expansion of 670 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits.NA16228,FRDA,FXN,Double Expansion,Female,46.179908083262,150,670/830,(GAA)n EXPANSION,Illumina,Clinically affected; onset at 12 years of age; ataxia; areflexia; weakness; scoliosis; nystagmus; affected sister is GM16227; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 670 and 830 repeats.NA16237,FRDA,FXN,Carrier,Female,43.0490154035068,150,700,(GAA)n EXPANSION,Illumina,Clinically unaffected carrier; mother of an affected son (GM16243); donor subject has one allele with GAA triplet repeat expansion of 700 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits.NA16243,FRDA,FXN,Double Expansion,Male,46.517913683568,150,670/1170,(GAA)n EXPANSION,Illumina,Clinically affected; age of onset 14; ataxia; cardiomyopathy; areflexia; weakness; sensory loss; dysarthria; scoliosis; reduced visual acuity; hearing loss; affected sister; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 670 and 1170 repeats.NA16240,FRDA,FXN,Carrier,Male,46.2081850076381,150,830,(GAA)n EXPANSION,Illumina,Clinically unaffected carrier; father of affected child; donor subject has one allele with GAA triplet repeat expansion of 830 in the first intron of the frataxin gene and the 2nd allele has a # of GAA repeats within normal limits.NA16207,FRDA,FXN,Double Expansion,Female,49.7895600404975,150,280/830,(GAA)n EXPANSION,Illumina,Clinically affected; age of onset 23; ataxia; areflexia; weakness; sensory loss; dysarthria; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 280 and 830 repeats.NA06895,FXS,FMR1,Normal,Male,45.5523989088931,150,23,(CGG)n EXPANSION,Illumina,"Clinically normal; 1 affected son and 2 grandsons; 46,XY in peripheral blood lymphocytes; normal male by Southern and PCR analyses; CGG repeat is 23"NA04025,FXS,FMR1,Expansion,Male,49.430236602306,150,645,(CGG)n EXPANSION,Illumina,"Macro-orchidism; mental retardation; 52% 46,fra(X)(q27),Y in PBL and 4% in fibroblasts; fra(X) observed in 0 to 50% of lymphoblasts using FudR; G6PD type A in blood; see GM04024 Fibroblast; CGG repeat size of 645 in the FMR1 gene as detected by PCR (normal size range is 5-45 repeats); full mutation (fully methylated) characteristic of Fragile X syndrome."NA04926,FXS,FMR1,Expansion,Male,48.8545969114385,150,NA,(CGG)n EXPANSION,Illumina,"Mental retardation and macro-orchidism; 46,fra(X)(q2800),Y in PBL; similarly affected brother and cousins; affected male by Southern analysis"NA05131,FXS,FMR1,Expansion,Male,44.5448196710185,150,NA,(CGG)n EXPANSION,Illumina,"Affected male by Southern analysis; 46, fra(X)(q27),Y in PBL; 8% of fibroblasts show fra(X) with FudR; mother is GM05855B Lymphoid; similarly affected brother and uncle."NA05185,FXS,FMR1,Expansion,Male,44.190542245323,150,NA,(CGG)n EXPANSION,Illumina,"46,fra(X),Y present in 30-50% of PBL; affected male by Southern analysis"NA09145,FXS,FMR1,Expansion,Male,47.1163211866408,150,NA,(CGG)n EXPANSION,Illumina,"Clinically affected; hyperactive, developmental delay, seizures, and esotropia;46,fra(X)(q27,Y in PBL;full expansion by Southern analysis;son of GM06863."NA09237,FXS,FMR1,Expansion,Male,47.9042189884893,150,931-940,(CGG)n EXPANSION,Illumina,"Low-normal IQ; hyperactive; short attention span; 46,fra(X)(q27),Y in PBL; CGG repeats in the FMR1 gene range from 931-940 (normal size range is 5-45 repeats); full mutation (fully methylated) characteristic of Fragile X syndrome; son of GM09238."NA07063,FXS,FMR1,NA,Female,77.3911929316335,150,NA,(CGG)n EXPANSION,Illumina,Slow learner; 14/50 blood lymphocytes showed fra(X); 4 affected cousins; daughter of GM07064A; 7% of lymphoblasts were positive for the Xq27-28 fragile site; carrier female by Southern analysisNA07539,FXS,FMR1,Normal,Male,49.1098134941507,150,23,(CGG)n EXPANSION,Illumina,"Clinically normal; normal male by Southern & PCR analyses; 46,XY in PBL; CGG repeat is 23; brother of GM07536."NA06890,FXS,FMR1,Normal,Male,42.5443823266974,150,30,(CGG)n EXPANSION,Illumina,"Clinically normal; affected brother and 2 nephews; 46,XY in peripheral blood lymphocytes; normal male by Southern and PCR analyses; CGG repeat is 30"NA06905,FXS,FMR1,Premutation,Female,46.0743235124888,150,23/70,(CGG)n EXPANSION,Illumina,Clinically normal; 1 affected son and great-grandson; negative for fra(X) in PBL; carrier female by Southern and PCR analyses; CGG repeats are 70 and 23NA07536,FXS,FMR1,Normal,Male,47.3683752970818,150,23,(CGG)n EXPANSION,Illumina,"Clinically normal; possible normal ""carrier""; 46,XY in PBL; normal male by Southern & PCR analyses; CGG repeat is 23"NA07540,FXS,FMR1,Normal,Female,47.5379808434543,150,23/29,(CGG)n EXPANSION,Illumina,Clinically normal; sister of GM07536; negative for fra(X) in PBL; normal female by Southern and PCR analyses; CGG repeats are 29 & 23NA07542,FXS,FMR1,Normal,Male,46.8860643957427,150,23,(CGG)n EXPANSION,Illumina,"Clinically normal; twin of GM07536; 46, XY in PBL; normal male by Southern & PCR analyses; CGG repeat is 23"NA06910,FXS,FMR1,Premutation,Female,45.9772923047645,150,30/75-89,(CGG)n EXPANSION,Illumina,Clinically normal; negative for fra(X) in PBL; carrier female by Southern and PCR analyses; CGG repeats are 75-89 and 30NA06894,FXS,FMR1,Premutation,Female,43.2503262059452,150,30/78,(CGG)n EXPANSION,Illumina,"Clinically normal; 1 affected son and 2 grandsons; 46,XX in peripheral blood lymphocytes; carrier female by Southern and PCR analyses; CGG repeats are 78 and 30"NA07541,FXS,FMR1,Normal,Female,48.4070544622506,150,29/30,(CGG)n EXPANSION,Illumina,Clinically normal; daughter of GM07540; negative for fra(X) in PBL; normal female by Southern and PCR analyses; CGG repeats are 31and 29NA07175,FXS,FMR1,Normal,Female,45.001431833438,150,23/30,(CGG)n EXPANSION,Illumina,"Clinically normal; 46,XX in PBL; affected brother and 2 nephews; normal female by Southern and PCR analyses; CGG repeats are 30 and 23"NA06889,FXS,FMR1,Normal,Female,46.0126497264435,150,23/30,(CGG)n EXPANSION,Illumina,"Clinically normal; possible heterozygote; affected brother and 2 nephews; 46, XX in peripheral blood lymphocytes; normal female by Southern and PCR analyses; CGG repeats are 30 and 23"NA06893,FXS,FMR1,Normal,Female,39.5781997555039,150,23/30,(CGG)n EXPANSION,Illumina,"Clinically normal; affected brother and 2 nephews; 46,XX in PBL; normal female by Southern and PCR analyses; CGG repeats are 30 and 23"NA06896,FXS,FMR1,Premutation,Female,45.9930733474211,150,23/95-140,(CGG)n EXPANSION,Illumina,Clinically normal; 2 affected sons and a brother; negative for fra(X) in PBL; carrier female by Southern and PCR analyses; CGG repeats are 95-120-140 and 23NA07538,FXS,FMR1,Normal,Female,46.5929455657073,150,29/29,(CGG)n EXPANSION,Illumina,Clinically normal; 1 affected brother; daughter of GM07537A; negative for fra(X) in PBL; normal female by Southern and PCR analyses; CGG repeats are 29 and 29NA07537,FXS,FMR1,Expansion,Female,46.8994742982495,150,28-29/>200?,(CGG)n EXPANSION,Illumina,Clinically normal; positive for fra(X) in PBL; carrier female by Southern and PCR analyses; PCR analysis shows that 1 allele has CGG repeats of 28-29 and a second allele possibly has the full mutation with greater than 200 repeats; sister of GM07536; 1 affected son and 2 affected grandsons.NA06897,FXS,FMR1,Expansion,Male,42.3345646019128,150,477,(CGG)n EXPANSION,Illumina,"Mental retardation; typical facies; large ears; macro-orchidism; 46,fra(X)(q27),Y in PBLs; in lymph culture, 2% of cells are positive with methotrexate and 6% are positive with FudR; low but detectable FMR-1 gene expression; CGG repeat size of 477 in the FMR1 gene as detected by PCR (normal size range is 5-45 repeats); full mutation (fully methylated) characteristic of Fragile X syndrome."NA07174,FXS,FMR1,Normal,Male,45.1165954924511,150,30,(CGG)n EXPANSION,Illumina,"46,XY in PBL; could be a ""non-expressing male"" based upon family history: affected brother and 2 nephews; normal male by Southern and PCR analyses; CGG repeat is 30; DNA obtained from the donor subject's lymphoblastoid cell line was sequenced in triplicate and the average CGG repeat in the FMR1 gene is 30"NA06903,FXS,FMR1,Premutation,Female,39.5374731103411,150,23/95,(CGG)n EXPANSION,Illumina,Clinically normal; affected son is GM06852A; daughter of GM06904A and GM06906A; negative for fra(X) in peripheral blood lymphocytes; carrier female by Southern and PCR analyses; CGG repeats are 95 and 23NA07543,FXS,FMR1,Normal,Female,46.3803712518592,150,20/29,(CGG)n EXPANSION,Illumina,Clinically normal; 5 sibs with mental retardation; mother is affected sister of GM07536; negative for fra(X) in PBL; normal female by Southern & PCR analyses; CGG repeats are 29 & 20NA06852,FXS,FMR1,Expansion,Male,45.3070746629254,150,>200,(CGG)n EXPANSION,Illumina,"Seizures; borderline IQ; large ears; positive family history for fra(X) and mental retardation; 46,fra(X)(q27),Y in PBL but not observed in lymphoblast culture; son of GM06903A; affected male by Southern and PCR analyses; CGG repeats >200"NA06891,FXS,FMR1,Premutation,Male,42.3700304689627,150,100-117,(CGG)n EXPANSION,Illumina,Clinically normal; affected brother and 2 nephews; negative for fra(X) in peripheral blood lymphocytes; normal transmitting male by Southern and PCR analyses; CGG repeat is 100-117; DNA obtained from the donor subject's lymphoblastoid cell line was sequenced in triplicate and the average CGG repeat in the FMR1 gene is 118NA06907,FXS,FMR1,Premutation,Female,43.9892092943397,150,29/85,(CGG)n EXPANSION,Illumina,Clinically normal; affected nephew and uncle; sister of GM06903A; daughter of GM06904A and GM06906A; negative for fra(X) in PBL; carrier female by Southern and PCR analyses; CGG repeats are 85 and 29NA06906,FXS,FMR1,Premutation,Male,46.2108781242456,150,96,(CGG)n EXPANSION,Illumina,"Clinically normal; affected brother and grandson; son of GM06905A; husband of GM06904A; father of GM06903A and GM06907A; suspected ""carrier"" and negative for fra(X) in both PBL and lymph culture; normal transmitting male by Southern and PCR analyses; CGG repeat is 85-90; DNA obtained from the donor subject's lymphoblastoid cell line was sequenced in triplicate and the average CGG repeat in the FMR1 gene is 96"NA06892,FXS,FMR1,Premutation,Male,46.671454529184,150,80-85,(CGG)n EXPANSION,Illumina,"Clinically normal; affected grandson and 2 great-grandsons; suspected non-expressing ""carrier""; 46,XY in peripheral blood lymphocytes and lymphoid culture; normal transmitting male by Southern and PCR analyses; CGG repeat is 80-85; DNA obtained from the donor subject's lymphoblastoid cell line was sequenced in triplicate and the average CGG repeat in the FMR1 gene is 93"NA06904,FXS,FMR1,Normal,Female,46.2016798483005,150,23/29,(CGG)n EXPANSION,Illumina,Clinically normal; spouse of GM06906A; mother of GM06903A and 06907A; 1 affected grandson; negative for fra(X) in PBL; normal female by Southern and PCR analyses; CGG repeats are 29 and 23NA06968,FXS,FMR1,Premutation,Female,46.0483102216434,150,32/107,(CGG)n EXPANSION,Illumina,"Obligate carrier; clinically normal; 1% of PBL show fra(X) with FudR or MTX; affected uncle and nephew; father is a normal ""carrier""; son is positive for fra (X); Proband is GM07071 Fibroblast; carrier of premutation by Southern analysis; CGG repeats are 107 and 32."NA07294,FXS,FMR1,Expansion,Male,46.2029499516507,150,NA,(CGG)n EXPANSION,Illumina,"Institutionalized for mental retard; 46, fra(X)(q27),Y in 32% of PBL; G6PD type A+; a twin, not identical by HLA typing, is institutionalized but not known if mentally retarded; negative for FMR-1 gene expression; affected male by Southern analysis"NA09316,FXS,FMR1,Expansion,Male,47.392577296921,150,NA,(CGG)n EXPANSION,Illumina,"46,fra(X)(q27),Y in 6% of PBL; institutionalized; mild mental retardation; affected male by Southern analysis"NA09317,FXS,FMR1,Expansion,Male,45.745132947253,150,NA,(CGG)n EXPANSION,Illumina,"46,fra(X)(q27),Y in 12% of PBL; institutionalized; mild mental retardation; negative for FMR-1 gene expression; affected male by Southern analysis"NA09497,FXS,FMR1,Expansion,Male,47.7726880972237,150,NA,(CGG)n EXPANSION,Illumina,20% of PBL are positive for fra(X); similarly affected brother; large ears; macro-orchidism; mental retardation; hyperactive behavior; affected male by Southern analysis; mother is GM09444 LymphoidNA07730,FXS,FMR1,Expansion,Male,47.6732782374295,150,NA,(CGG)n EXPANSION,Illumina,Placental fibroblast culture; 2 affected maternal uncles have fra(X)(q27); 6% of cultured amniotic fluid cells and 26% of placental fibroblasts showed the fra(X); affected male by Southern analysisCD00014,FXS,FMR1,Premutation,Male,49.2982304817056,150,56,(CGG)n EXPANSION,Illumina,CGG repeat is 56 as reported by the National Institute of Standards and Technology (NIST)NA03200,FXS,FMR1,Expansion,Male,48.8052071642461,150,NA,(CGG)n EXPANSION,Illumina,"46,fra(X)(q27),Y; 17% in PBL and 7 to 50% of lymphoblasts using FudR; negative for FMR-1 gene expression; affected male by Southern analysis"NA20235,FXS,FMR1,Normal,Female,45.5823978265837,150,29/45,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat sizes of 29 in allele 1 and 45 in allele 2 in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20238,FXS,FMR1,Normal,Female,43.1247803972731,150,29/30,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat sizes of 29 in allele 1 and 30 in allele 2 in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20237,FXS,FMR1,Premutation,Male,45.5891655000244,150,100-104,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat size of between 100-104 in 1 allele in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods each; neither method provided a consensusNA20239,FXS,FMR1,Premutation,Female,44.8250627424828,150,20/183-193,(CGG)n EXPANSION,Illumina,Clinically unaffected; full mutation; donor subject has CGG repeat sizes of 20 in allele 1 and between 183-193 in allele 2 in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods each; neither method provided a consensus on allele twoNA20242,FXS,FMR1,Premutation,Female,42.5965680089773,150,30/73,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat sizes of 30 in allele 1 and 73 in allele 2 in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20243,FXS,FMR1,Normal,Female,42.5035626591934,150,29/41,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat sizes of 29 in allele 1 and 41 in allele 2 in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20230,FXS,FMR1,Normal,Male,46.3536197200697,150,53,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat size of 53 in 1 allele in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20232,FXS,FMR1,Normal,Male,46.7711246006676,150,46,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat size of 46 in 1 allele in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20233,FXS,FMR1,Premutation,Male,46.8639402331816,150,117,(CGG)n EXPANSION,Illumina,Clinically unaffected; probable fragile X tremor/ataxia syndrome (FXTAS); donor subject has CGG repeat size of 117 in 1 allele in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods each; only one method provided a consensusNA20234,FXS,FMR1,Normal,Female,47.2067640399163,150,31/46,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat sizes of 31 in allele 1 and 46 in allele 2 in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20236,FXS,FMR1,Normal,Female,45.1308265029618,150,31/53,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat sizes of 31 in allele 1 and 53 in allele 2 in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20231,FXS,FMR1,Premutation,Male,45.5157040244672,150,76,(CGG)n EXPANSION,Illumina,Clinically unaffected; Donor subject has CGG repeat size of 76 in 1 allele in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20240,FXS,FMR1,Premutation,Female,43.4229700100459,150,30/80,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat sizes of 30 in allele 1 and 80 in allele 2 in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA20241,FXS,FMR1,Premutation,Female,43.5501479424192,150,29/93-110,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has CGG repeat sizes of 29 in allele 1 and between 93-110 in allele 2 in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods each; neither method provided a consensus on allele twoNA20244,FXS,FMR1,Normal,Male,45.8333367967441,150,41,(CGG)n EXPANSION,Illumina,Clinically unaffected; donor subject has a CGG repeat size of 41 in 1 allele in the 5 prime untranslated region (UTR) of the FMR1 gene; CGG repeat size was determined by testing in 9 independent laboratories using two methods eachNA07862,FXS,FMR1,Expansion,Male,47.322309237105,150,501-550,(CGG)n EXPANSION,Illumina,Mental retardation; typical facies; large testes; hyperactive; affected monozygotic twin brother is GM07861; CGG repeats in the FMR1 gene range from 501-550 as detected by PCR (normal size range is 5-45 repeats); full mutation (fully methylated) characteristic of Fragile X syndrome.NA13509,HD,HTT,Expansion,Female,47.0544125762083,150,15/70,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 70 and 15; see GM21756 FibroblastNA13515,HD,HTT,Expansion,Male,49.0678188694084,150,16/66,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 66 and 16; see GM21757 FibroblastCD00022,HD,HTT,Premutation,Female,47.8708219020957,150,18/31,(CAG)n EXPANSION,Illumina,CAG repeats in the HD gene are 31 and 18NA13507,HD,HTT,Expansion,Male,35.8859208073793,150,15/55,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 55 and 15.NA13508,HD,HTT,Expansion,Male,46.0100982318932,150,22/58,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 58 and 22.NA13510,HD,HTT,Expansion,Male,45.8662807888972,150,15/44,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 44 and 15.NA13511,HD,HTT,Expansion,Male,47.4461460283252,150,45/47,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 47 and 45.NA13512,HD,HTT,Expansion,Female,46.8036660169538,150,16/44,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 44 and 16.NA13513,HD,HTT,Expansion,Female,48.8753213823697,150,15/49,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 49 and 15.NA13514,HD,HTT,Expansion,Female,48.0494268035157,150,15/52,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 52 and 15.NA13503,HD,HTT,Expansion,Female,44.2497120137793,150,17/45,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 45 and 17.NA13504,HD,HTT,Expansion,Male,45.4817816576975,150,16/46,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 46 and 16.NA13505,HD,HTT,Expansion,Male,49.6367071829747,150,22/50,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 50 and 22.NA13506,HD,HTT,Expansion,Male,42.201349472378,150,17/48,(CAG)n EXPANSION,Illumina,Clinically affected; expanded CAG repeat HD alleles are 48 and 17.NA06926,SCA1,ATXN1,Expansion,Male,44.7018083265633,150,29/52,(CAG)n EXPANSION,Illumina,Olivopontocerebellar atrophy type 1; spinocerebellar ataxia; 6 affected generations; see GM06927 Fibroblast; analysis of ATXN1 (ATX1) alleles showed normal allele with 29 CAG repeats and expanded allele with 52 repeatsNA13536,SCA1,ATXN1,Expansion,Female,44.7006220210627,150,31/43,(CAG)n EXPANSION,Illumina,Ataxia; 6 affected generations in pedigree; analysis of ATXN1 (ATX1) alleles showed normal allele with 31 CAG repeats and expanded allele with 43 repeatsNA13537,SCA1,ATXN1,Expansion,Male,46.7274540225836,150,32/60,(CAG)n EXPANSION,Illumina,Ataxia; dysarthria; amyotrophy; dysphagia; analysis of ATXN1 (ATX1) alleles showed normal allele with 32 CAG repeats and expanded allele with 60 repeatsNA06151,SCA3,ATXN3,Expansion,Male,43.1504425301542,150,24/74,(CAG)n EXPANSION,Illumina,"Portuguese; affected father and two sibs; SCA Type III (SCA3): ataxia, nystagmus, and dysarthria; allele 1 has 24 CAG repeats in the ATXN3 (MJD) gene; allele 2 has 74 CAG repeats"NA23709,SMBA,AR,Expansion,Male,48.9019583690766,150,51,(CAG)n EXPANSION,Illumina,Clinically affected; onset of symptoms at age 45; this subject has 51 CAG trinucleotide repeats in the first exon of the androgen receptor gene (AR)(normal range= 4-33 copies); positive family history: maternal grandfather had severe leg weakness and 3 male cousins have tested positive for SBMA (samples from family are not in repository).8,HD,HTT,Expansion,Male,41.6532084912176,151,16/45,(CAG)n EXPANSION,NYGC,Nano 450bp Xv19,HD,HTT,Expansion,Female,42.0306846948711,151,20/42,(CAG)n EXPANSION,NYGC,Nano 450bp Xv1170,HD,HTT,Expansion,Female,39.0934804685766,151,40/50,(CAG)n EXPANSION,NYGC,Nano 450bp Xv1171,HD,HTT,Normal,Male,43.1862592333329,151,17/18,(CAG)n EXPANSION,NYGC,Nano 450bp Xv1192,HD,HTT,Expansion,Male,38.9188949278056,151,21/45,(CAG)n EXPANSION,NYGC,Nano 450bp Xv1193,HD,HTT,Normal,Female,42.5843397717109,151,18/22,(CAG)n EXPANSION,NYGC,Nano 450bp Xv1196,HD,HTT,Expansion,Male,48.0465457194887,151,22/68,(CAG)n EXPANSION,NYGC,Nano 450bp Xv1197,HD,HTT,Expansion,Female,42.7200327121633,151,22/63,(CAG)n EXPANSION,NYGC,Nano 450bp Xv1975,HD,HTT,Expansion,Female,38.1201687794827,151,19/45,(CAG)n EXPANSION,NYGC,Nano 450bp Xv1988,HD,HTT,Expansion,Female,39.1973558941359,151,19/43,(CAG)n EXPANSION,NYGC,Nano 450bp Xv11042,HD,HTT,Expansion,Male,43.1235104987577,151,22/47,(CAG)n EXPANSION,NYGC,Nano 450bp Xv11133,HD,HTT,Premutation,Female,39.6867423665119,151,19/37,(CAG)n EXPANSION,NYGC,Nano 450bp Xv14271,HD,HTT,Expansion,Female,48.3506747544869,151,20/40,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"6779,HD,HTT,Expansion,Male,55.9443897361758,151,20/41,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"6783,HD,HTT,Expansion,Female,47.8895459104111,151,20/40,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"6782,HD,HTT,Expansion,Male,46.5464940229141,151,24/41,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"932,HD,HTT,Expansion,Female,39.5636529134281,151,14/46,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"994,HD,HTT,Normal,Male,45.9634011356336,151,17/17,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"1002,HD,HTT,Expansion,Female,44.8507303852414,151,17/46,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"931,HD,HTT,Expansion,Male,69.2239765186095,151,18/45,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"2992,HD,HTT,Expansion,Female,44.0331610502063,151,18/43,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"2993,HD,HTT,Expansion,Female,50.2092027768389,151,18/44,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"2996,HD,HTT,Expansion,Female,44.7026480562548,151,18/46,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"964,HD,HTT,Normal,Male,44.6913166244464,151,19/19,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"963,HD,HTT,Expansion,Female,42.4368131772949,151,14/48,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"981,HD,HTT,Expansion,Female,47.8266502336229,151,19/46,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"985,HD,HTT,Expansion,Female,57.1643775289324,151,19/46,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"119,HD,HTT,Expansion,Female,46.6073550359091,151,20/41,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"154,HD,HTT,Expansion,Female,42.1236904549048,151,16/45,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"172,HD,HTT,Expansion,Male,46.9376917209709,151,16/43,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"174,HD,HTT,Expansion,Female,38.6583020292561,151,20/48,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"182,HD,HTT,Expansion,Male,43.3189925154002,151,20/48,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"166,HD,HTT,Expansion,Female,38.5803289460833,151,45/52,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"195,HD,HTT,Expansion,Male,39.8951911719844,151,18/52,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"1043,HD,HTT,Expansion,Female,43.3185441464112,151,18/48,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"1049,HD,HTT,Expansion,Male,40.0774873216412,151,22/45,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"149,HD,HTT,Expansion,Male,43.9717248700323,151,42/46,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"173,HD,HTT,Expansion,Male,47.0520635246093,151,44/47,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"179,HD,HTT,Expansion,Female,35.5959623493898,151,42/42,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"933,HD,HTT,Expansion,Male,37.2759661248244,151,42/46,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"2999,HD,HTT,Expansion,Female,52.6477632754218,151,43/47,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"3000,HD,HTT,Expansion,Female,56.5685336362407,151,18/44,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"4709,HD,HTT,Expansion,Male,45.7486173512361,151,46/51,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"598,HD,HTT,Expansion,Male,41.7744982840895,151,21/42,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"3423,HD,HTT,Expansion,Male,49.6766957032236,151,20/43,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"4381,HD,HTT,Expansion,Female,55.0370663825377,151,18/45,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"346,HD,HTT,Expansion,Male,42.3715275851703,151,17/44,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"587,HD,HTT,Expansion,Male,68.5646039902571,151,15/45,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"1208,HD,HTT,Expansion,Female,63.1296733516225,151,20/47,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"4399,HD,HTT,Expansion,Female,53.6662723882606,151,18/45,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"198,HD,HTT,Expansion,Male,47.0258230935116,151,22/86,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"297,HD,HTT,Expansion,Male,42.4210297532506,151,18/47,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"653,HD,HTT,Expansion,Female,51.2220767161541,151,15/78,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"832,HD,HTT,Expansion,Female,41.573883624042,151,20/44,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"843,HD,HTT,Expansion,Male,43.6006296625828,151,17/43,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"965,HD,HTT,Expansion,Female,50.0617427289182,151,19/44,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"581,HD,HTT,Expansion,Female,45.4660041058784,151,33/44,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5"973,HD,HTT,Premutation,Male,44.862586695246,151,19/48,(CAG)n EXPANSION,NYGC,"PCR-free 450bp, Xv2.5",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
